Investment Thesis
MoonLake is a pre-revenue biotech company burning $66.3M per operating period with losses accelerating (EPS down 86.8% YoY), indicating worsening operational efficiency. While the $298.5M cash position provides runway for approximately 18-20 months, the fundamental deterioration in losses combined with zero revenue generation presents a high-risk financial profile dependent entirely on future clinical success.
Strengths
- Strong cash position of $298.5M (75% of total assets) provides operational runway
- Excellent liquidity with 8.60x current and quick ratios indicating ability to meet short-term obligations
- Moderate leverage with 0.39x debt-to-equity ratio, manageable debt burden
Risks
- No revenue generation; company remains pre-commercial with zero sales
- Accelerating operating losses ($70M in latest period) with net loss worsening 86.8% YoY on EPS basis
- Negative cash burn of $66.3M per period exhausts cash runway in approximately 18-20 months without revenue inflection or additional funding
- Negative ROE (-27.4%) and ROA (-17.4%) indicate shareholder value destruction
- All profitability metrics unavailable or negative; no evidence of path to positive unit economics
Key Metrics to Watch
- Operating cash burn rate and cash runway depletion timeline
- Revenue recognition milestones and commercial product launch timeline
- Quarterly net losses trend and operating margin trajectory
Financial Metrics
Revenue
N/A
Net Income
-69.7M
EPS (Diluted)
$-0.98
Free Cash Flow
-66.3M
Total Assets
400.4M
Cash
298.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-27.4%
ROA
-17.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.60x
Quick Ratio
8.60x
Debt/Equity
0.39x
Debt/Assets
36.6%
Interest Coverage
-106,581.43x
Long-term Debt
99.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:53:37.743604 |
Data as of: 2026-03-31 |
Powered by Claude AI